Introduction {#S0005}
============

Acute respiratory tract infections (ARTIs) are a leading cause of morbidity and mortality in children worldwide\[[@CIT0001], [@CIT0002]\]. Many viruses are associated with respiratory syndromes in all age groups\[[@CIT0003], [@CIT0004]\]. However, inadequate diagnostic methods and unknown viral pathogens limit current understanding of ARTI etiology.

One known viral pathogen, human metapneumovirus (hMPV), is a globally distributed pathogen associated with respiratory infection in children\[[@CIT0005]--[@CIT0015]\]. After the pathogen respiratory syncytial virus (RSV), hMPV is the leading cause of respiratory infection in children in influenza off-seasons. One study suggested that, in China, *almost* all children are exposed to hMPV by 6 years of age\[[@CIT0016]\]. In Chongqing, China, hMPV was found in children with ARTIs\[[@CIT0017]\]. These studies suggest that hMPV has significant epidemiological and pathological impacts as a significant respiratory pathogen in children.

Previous hMPV studies focused on its epidemiological characteristics and compared its viral genetics to those of RSV. However, whether the hMPV viral load is correlated with the severity of respiratory infection remains unknown.

Compared to conventional methods, such as virus culture and indirect immunofluorescence, real-time reverse transcriptase polymerase chain reaction (real-time PCR) is more sensitive and efficient at quantifying viral load\[[@CIT0018]--[@CIT0020]\]. With real-time RT-PCR, we evaluated the changes in hMPV viral load every-other-day from 18 hospitalized children with lower respiratory tract infections to elucidate the association of hMPV viral load in airway with the disease course and severity.

Subjects and Methods {#S0006}
====================

**Patients\'clinical data and NPAs collection:** Eighteen children hospitalized in the respiratory medicine division of Children\'s Hospital of Chongqing Medical University from December 2007 to January 2008 with LRTIs were enrolled in the study. Parents of all 18 patients gave the consent for intervention. Besides, all the protocols have been approved by Institutional Review Board, Chongqing Medical University. For each patient following clinical data were collected: age at sample collection, gender, diagnosis, days since onset of illness, hospitalization duration, co-infection, and outcome of illness ([Table 1](#T0001){ref-type="table"}). The scoring system used for respiratory disease severity assessment in children has been reported by Wang et al\[[@CIT0021]\], Nasr et al\[[@CIT0022]\], Mandelberg\[[@CIT0023]\] and others.

###### 

Clinical characteristics and descriptors for the 18 hMPV-positive cases

  Case     Sex      Age (month)   RSV by PCR   Sputum culture                                     Onset days   Diagnosis                                     Length of stay   Outcome
  -------- -------- ------------- ------------ -------------------------------------------------- ------------ --------------------------------------------- ---------------- ----------
  **1**    male     6.6           \+           Moraxella catarrhalis                              4            bronchiolitis                                 6                cured
  **2**    male     3.6           ++           \-                                                 5            bronchiolitis                                 7                cured
  **3**    female   1.7           \+           \-                                                 1            pneumonia                                     10               cured
  **4**    male     2.7           −            Hemophilus parainfluenzae                          7            bronchiolitis/diarrhea                        7                cured
  **5**    female   3.5           \+           Hemophilus parainfluenzae/ Moraxella catarrhalis   6            pneumonia                                     6                cured
  **6**    male     3.4           \-           \-                                                 27           pneumonia                                     11               cured
  **7**    male     3             −            Hemophilus parainfluenzae                          9            bronchiolitis/diarrhea                        8                cured
  **8**    female   2             \+           \-                                                 2            bronchiolitis                                 8                cured
  **9**    male     5             \-           \-                                                 15           pneumonia/diarrhea                            3                improved
  **10**   female   2             −            Klebsiella pneumonia                               15           bronchiolitis                                 5                cured
  **11**   male     5             \+           Streptococcus pneumonia                            4            bronchiolitis                                 6                cured
  **12**   male     14            −            \-                                                 6            asthma/pneumonia/anemia                       7                cured
  **13**   male     17            \+           \-                                                 20           pneumonia/congenital heart disease/diarrhea   7                cured
  **14**   male     11.5          \-           \-                                                 7            bronchiolitis                                 3                improved
  **15**   female   29            \+           \-                                                 7            pneumonia                                     6                cured
  **16**   male     4.7           \+           \-                                                 6            bronchiolitis                                 8                cured
  **17**   male     16            ++           MP+/ Streptococcus pneumonia                       9            pneumonia/anemia                              9                cured
  **18**   male     6             \+           Staphylococcus aureus                              14           pneumonia/laryngitis/otitis media/diarrhea    2                improved

A severity score was assigned for each of four categories (respiratory rate, retractions, wheeze, and general appearance). A single point was given to patients with a respiratory rate of 31 to 45 breaths/min, or wheezing at terminal expiration or audible only with stethoscope, or intercostal retraction, and normal general condition. Two points were given to patients with a respiratory rate of 45 to 60 breaths/min, or wheezing during the entire expiration or audible on expiration without stethoscope, or tracheosternal retractions, and stable general condition. Three points were given to patients with a respiratory rate over 60 breaths/min, or inspiratory and expiratory wheezing without stethoscope, or severe retraction with nasal flaring, or disturbance of general condition including irritability, lethargy, and poor feeding. For each patient, the total severity score was calculated by summing the score for each category. Oxygen saturation and the need for supplemental oxygen were also recorded. Oxygen saturation was measured using Nellcor Oximeter (HEMENS, SC6002XL).

From each patient, about 0.5 ml NPA sample was collected every time. NPAs were sampled every-other-day during hospitalization. Overall, 68 NPAs were collected from the 18 hMPV-positive children. Each sample was centrifuged twice at 1500 rpm for 10 min. Between the two centrifugations, 1 ml of PBS was added to each sample. After centrifugation, supernatants of NPAs were labeled and stored at −70°C for future batch detection.

**RT-PCR for hMPV and RSV detection:** The supernatants of NPAs were used as templates for real-time RT-PCR of the fusion glycoprotein (F) gene from hMPV and for the G glycoprotein (G) gene from RSV. Total RNA was extracted from each NPA sample with the QIAamp Viral RNA Kit (QIAGEN, Hilden, Germany) according to the manufacturer\'s protocol. Approximately 6.5 µl of each RNA sample was incubated in a solution containing 100 µM of random 6-mers and 50 µM of Oligo-dT Primer (PrimeScript^TM^ RT reagent Kit, TaKaRa) in a final volume of 10 µl at 37°C for 15 min followed by 5 s at 85°C to synthesize cDNA. The F gene from hMPV was amplified using virus specific primers (10 µM), ([Table 2](#T0002){ref-type="table"}) in a 25 µl reaction mixture containing 2 µl cDNA, 8.5 µl ddH~2~O, 12.5 µl 2×Master Mix, and 1 µl forward and 1 µl reverse primer for hMPV virus; and 25 µl reaction for amplification of G gene from RSV containing 3 µl cDNA, and 22 µl Master Mixture including 200 µM dNTPs, 1.5 mM MgCl~2~, 1.5 U Taq DNA polymerase, and 50 pM of each of the forward and reverse primers for RSV virus. The PCR cycling conditions for hMPV included initial denaturation at 94°C for 4 min, followed by 40 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min. At the end, 72°C for 10 min again; the PCR cycling conditions for RSV included initial denaturation at 94°C for 3 min, followed by 33 cycles of 94°C for 1 min, 50°C for 1min and 72°C for 1.5 min. Finally, again 72°C for 10 min. Products were visualized on agarose gels.

###### 

Sequences of primers and probes for detection of hMPV and RSV

  Target     Primer/probe name   Position at the 5end of strain   Primer/probe sequence (5--3)
  ---------- ------------------- -------------------------------- ----------------------------------------
  **hMPV**   hMPVF(real-time)    38                               CGTTTCTTACATGCCGACATCTG
  hMPV       hMPVR(real-time)    143                              GCTCCCGTAGACCCCTATCAG
  **hMPV**   hMPVP               89                               (FAM)CCCTTTCTTCGCACCATCGCACGG(Eclipse)
  **hMPV**   hMPVF               3705                             TTTGGACTTAATGACAGATG
  **hMPV**   hMPVR               4154                             TCTTCCTGTGCTAACTTTG
  **RSV**    RSVF                170                              TGGGACACTCTTAATCAT
  **RSV**    RSVR                419                              TGATTCCAAGCTGAGGAT

**Real-time RT-PCR for hMPV viral load quantification:** Recombinant plasmids containing hMPV F gene were created as standards with a Topo TA Cloning Kit (Invitrogen, USA). After plasmid purification with the Plasmid Mini Kit I (OMEGA, USA), the concentration of the purified plasmid was calculated by absorption spectrophotometry with a Thermo NANODROP ND1000 (Biometra, Germany). Ten-fold serial dilutions (10^0^--10^7^ copies/µL) were used to construct a real-time PCR standard quantitative curve that showed an ideal linear relationship between the log values of initial template concentration and cycle threshold values. The hMPV F gene primers (4 µM) and probe sequences ([Table 2](#T0002){ref-type="table"}) were designed based on the prototype strain from China (GenBank accession number DQ336144). The PCR mixture consisted of 12.5 µL of 2× Probe Premix Ex Taq, 0.5 µl of each hMPV primer, 1 µl hMPV probe, and 2 µl of cDNA in a volume of 25 µl. The cDNA was amplified with Premix Ex Taq Kit (Perfect Real Time, TaKaRa) according to the manufacturer\'s protocol in a LightCycler instrument (CFX96 real-time system, Bio-Rad). The PCR had the following cycling conditions: an initial rapid increase to 95°C for 10 s, followed by 40 cycles of 5 s at 95°C, and 34 s at 60°C, with continuous fluorescence reading. The cycle threshold (Ct) was ≤36.

**Statistical analyses:** Viral load was calculated as the initial copy number per RT-PCR reaction. The correlation between course of illness or severity of illness and log~10~-transformed quantitative viral load was assessed with a general linear model of repeated measurement data with the log viral load as a continuous linear variable. The correlation of age or gender with the log viral load was evaluated by a multivariate stepwise regression analysis. SAS version 6.12 (SAS Institute, Cary, NC, USA) was used for all statistical analyses.

Findings {#S0007}
========

**Clinical data analysis:** Each hMPV-patient\'s clinical state was evaluated for respiratory rate, retractions, wheeze, and general appearance. The severity scores were divided into three categories: mild (0--4.9 points, state of illness=1), moderate (5-8.9 points, state of illness=2), and severe (9--12 points, state of illness=3). Among the 18 hMPV-positive children, 6 cases were mild, 8 cases moderate, and 4 cases severe. When SLE=0.1 and SLS=0.05, multivariate stepwise regression analyses revealed no significant correlation between age or gender (*P=0.1, P=0.07*).

The hMPV-positive patients ranged in age from 1 month to 29 months (median=7.5 months).

Among the patients, 13 were males and 5 females (male *to* female ratio=2.2:1*)*. The clinical symptoms were cough (100%), wheezing (72.2%), diarrhea (33.3%), fever (11.1%), hoarseness *(5*.6%), poor feeding, shortness of breath, *and* retraction sign of three fossae (22.2%). The clinical diagnoses were bronchiolitis (9 cases), pneumonia (9 cases), and pneumonia combined with asthma (1 case). The complications of the illness were congenital heart disease (1 case), anemia (2 cases), otitis media and laryngitis (1 case), and diarrhea (5 cases). The course of illness in these patients was classified into 3 categories: 5 days or less (5 cases), 6--11 days (8 cases), and 12 days or more (5 cases) with an average of 7.33 days. Fifteen patients made a full recovery. Of the 18 hMPV-positive patients, 11 were co-infected with another virus and/or bacteria ([Table 3](#T0003){ref-type="table"}). All co-infected patients were also RSV-positive.

###### 

Distribution of co-infection and single infection of hMPV in 18 hMPV-positive patients

  Pathogen                    Total   Single infection   Coinfection with bacteria virus bacteria and virus   MP/CP-IgM       
  --------------------------- ------- ------------------ ---------------------------------------------------- ----------- --- ---
  **hMPV**                    18      7                  8                                                    11          8   3
  **S. pneumoniae**                                      2                                                                    
  **H. parainfluenzae**                                  3                                                                    
  **Klebsiella pneumoniae**                              1                                                                    
  **Moraxella catarrhalis**                              2                                                                    
  **Staphylococcus aureus**                              1                                                                    
  **RSV**                                                                                                     11              

This table shows that there were 7 cases infected with hMPV only, and the other 11 cases of hMPV-positive were co-infected with virus and/or bacteria. All 8 cases of bacteria infections were co-infected with virus, and one was dual-infected with bacteria in 8 bacterial infections.

**Viral load:** Depending on the length of the illness, hMPV viral load was measured 2--6 times for each patient. The copies of viral load in case5, 7, 11, 14, 15, 16 and 17 were more than 1×10^5^ copies/RT-PCR reaction, and those in other cases are less than 1×10^5^ copies/RT-PCR reaction. Copies of viral load for each patient decreased with extension of course of disease and the hMPV almost could not be detected on discharge ([Table 4](#T0004){ref-type="table"}). Viral load was not correlated with disease severity (*P=0.5, 0.9, 0.5*) but was correlated with days after onset of illness ([Fig. 1](#F0001){ref-type="fig"}). When the hMPV-positive patients were grouped by the length of the course of illness (Group 1:≤5 days; Group 2: 6--11 days; Group 3:\>11 days), the viral load was significantly different between groups. Group 1 and 2 had significantly different log~10~ viral load values (*P=*0.01). Group 2 and 3 also had significantly different log~10~ viral load values (*P*=0.006). In contrast, Group 1 and 3 did not have significantly different log~10~ viral load values (*P=*0.4). Peak shedding time of hMPV was about 6--11 days post-infection.

![Correlation of log~10~--transformed hMPV viral load and severity of disease or days after onset of the illness. The severity is divided into three groups (mild, moderate and severe). The days after onset of illness are from about one day to thirty-seven days.](IJPD-20-393-g001){#F0001}

###### 

Every-other-day changes in hMPV viral load during the course of the disease. Copies/RT-PCR reaction×10^2^

  Case   Onset days   State of illness   Admission-(day 1)   Day 3     Day 5     Day 6     Day 7     Day 8     Day 9    Day 11
  ------ ------------ ------------------ ------------------- --------- --------- --------- --------- --------- -------- --------
  1      4            severe             137.896             233.235   740.814             63.836                       
  2      5            moderate           67.564              180.411   497.142             0                            
  3      1^+^         moderate           111.953             99.109    125.265             0                            
  4      7            mild               26.199              65.476    107.395             208.761                      
  5      6            mild               520.146             41748     23004               66.009                       
  6      27           moderate           243.885             148.504   474.351             329.724             249.21   0
  7      9            severe             2871.24             206.631             176.151             187.589            
  8      2            moderate           45.454              173.702   275.409             110.206             67.542   
  9      15           mild               328.659             113.401   22.067                                           
  10     15           moderate           241.542             105.542   68.948                                           70.567
  11     4^+^         moderate           164.159             210.188   13845               901.842                      
  12     6            mild               138.557             142.667   137.705             11.148                       
  13     20           moderate           130.889             199.027                                                    
  14     7            mild               2188.2              145.245                                                    
  15     7            mild               364.35              2225.85   220.668                                          
  16     6            severe             27.89               4568.85   897.369             121.431             0        
  17     9            moderate           1704                          362.1               276.9               0        
  18     14           severe             673.68              272.3                                                      

This shows the disease severity (mild, moderate or severe) and the length of the illness in 18 patients. Depending on the length of illness, hMPV viral load was measured 2-6 times for each patient. The copies of viral load in case 5, 7, 11, 14, 15, 16 and 17 are more than 1×10^5^ copies/RT-PCR reaction and those in other cases are less than 1×10^5^ copies/RT-PCR reaction. The copies of viral load for each patient decreased with extension of course of the disease.

Discussion {#S0008}
==========

Similar to the most common respiratory viral pathogen RSV, the recently identified hMPV was a major cause of LRTIs and other wheezing diseases. However, none of the previous hMPV studies had investigated if differences in hMPV viral load were correlated with differences in duration of course or severity of the respiratory duration of course or severity of the respiratory disease.

Similar to RSV and influenza infections, reported hMPV infections were seasonal, although sporadic infections arose throughout the year\[[@CIT0024], [@CIT0025]\]. Because we previously reported\[[@CIT0017]\] that hMPV infections were most common during winter and spring months in Chongqing area, we collected specimens in the winter. Among the 18 hMPV-positive cases, 11 patients were co-infected with RSV. Additionally, 8 of these 11 were also co-infected with bacteria. However, no significant difference was found in disease severity between patients with or without co-infection (*P*\>0.05). These findings are consistent with previous studies which showed that RSV/hMPV dual infection was overrepresented in RSV patients requiring mechanical ventilation, indicating that co-infection of RSV and hMPV did not lead to a more severe RSV infection\[[@CIT0026]\]. However, Bosis et al.\[[@CIT0027]\] found that hMPV viral load was correlated with disease severity and associated with short or long clinical course. In an analysis of bacterial co-infection in patients with community-acquired pneumonia, 32.5% likely had single bacterial infections and 15.2% had co-infections with bacteria and viruses\[[@CIT0028]\]. Further studies with this method should investigate whether bacterial and viral co-infection affects severity of other clinical diseases. Similar to what we found, mixed viral infections are common, especially for RSV and hmpv\[[@CIT0029]\]. Currently, there is conflicting evidence of whether dual infections are related to the disease severity\[[@CIT0030]--[@CIT0033]\] or not\[[@CIT0034]--[@CIT0036]\].

Future studies should focus on whether viral load, viral genotype, co-infection, or combinations of these factors are related to the severity of illness.

Previous studies divided hMPV patients into two categories: low viral load \<1×10^5^ copies and high viral load ≥1×10^5^ copies\[[@CIT0037], [@CIT0038]\]. Here, patients in the middle of the course of infection (6--11 days after onset) had a high viral load while patients at the beginning or end of the course of the illness had a low viral load. The severe clinical symptoms of patients with a low viral load might be attributed to long disease course or co-infection with other viruses and bacteria. Regardless, viral load was correlated with the course of the disease, in agreement with previous studies\[[@CIT0038]\]. Further studies should investigate whether clinical symptoms, severity, course of illness, and subsequent respiratory are associated with viral load of distinct hMPV subgroups.

It is possible that a correlation between viral load and disease severity exists, but it was not identified in our study. This missed association could stem from three major limitations for quantifying viral load. First, the NPAs were not always taken at the peak of acute LRTI, some were not collected until development of disease on the 15th day or after 1 month of onset. Second, patients often received therapy before hospitalization, especially in the form of steroids and bronchodilators. These treatments can interfere with clinical infection characteristics and/or virus replication. Third, it was not possible to perform a correct follow-up for all patients after discharge. Despite these limitations, we obtained hMPV viral loads in 18 hMPV-positive patients collected daily during the hospital visit. Our findings revealed that the hMPV load was significantly correlated with the course of illness.

The decrease of hMPV load indicated the beginning of recovery.

Conclusion {#S0009}
==========

hMPV load was significantly correlated with the course of illness. The association between hMPV viral load and the course of disease suggested that hMPV is an important pathogen in lower respiratory tract infection in children. But hMPV did not always lead to more severe respiratory illness.
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